A single dose of tumor vaccine targeting resistant tumors by dual T and NK cells was able to increase CD8+ and CD4+ T cell frequencies by 17.9 and 29.3 fold, and NK cell counts by about 40 fold, respectively, compared to the control in murine models (41). This evidence concerns the gene CD8A and neoplasm.